CHA
CRBP icon

Carmichael Hill & Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

Carmichael Hill & Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.06K Hold
100
– – ﹤0.01% 707
2024
Q2 		$4.53K Hold
100
– – ﹤0.01% 647
2024
Q1 		$3.92K Hold
100
– – ﹤0.01% 645
2023
Q4 		$604 Hold
100
– – ﹤0.01% 760
2023
Q3 		$674 Hold
100
– – ﹤0.01% 746
2023
Q2 		$784 Hold
100
– – ﹤0.01% 743
2023
Q1 		$727 Hold
100
– – ﹤0.01% 738
2022
Q4 		$332 Hold
100
– – ﹤0.01% 757
2022
Q3 		$0 Hold
100
– – ﹤0.01% 817
2022
Q2 		$1K Hold
100
– – ﹤0.01% 753
2022
Q1 		$2K Hold
100
– – ﹤0.01% 743
2021
Q4 		$2K Hold
100
– – ﹤0.01% 755
2021
Q3 		$3K Hold
100
– – ﹤0.01% 724
2021
Q2 		$5K Hold
100
– – ﹤0.01% 667
2021
Q1 		$6K Buy
100
+67
+203% +$4.4K ﹤0.01% 630
2020
Q4 		$1K Hold
33
– – ﹤0.01% 705
2020
Q3 		$2K Hold
33
– – ﹤0.01% 653
2020
Q2 		$8K Hold
33
– – 0.01% 517
2020
Q1 		$5K Hold
33
– – ﹤0.01% 526
2019
Q4 		$5K Buy
+33
New +$4.88K ﹤0.01% 549

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Carmichael Hill & Associates's CRBP Position: Q3 2024 in Review

Carmichael Hill & Associates held its Corbus Pharmaceuticals (CRBP) position steady in Q3 2024 at 100 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

Carmichael Hill & Associates first reported a position in CRBP in Q4 2019 and has held it in 20 quarters since. The position peaked at $8K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Carmichael Hill & Associates held 100 shares of Corbus Pharmaceuticals worth $2.06K as of Q3 2024.
  • Carmichael Hill & Associates left its Corbus Pharmaceuticals share count unchanged in Q3 2024.
  • Corbus Pharmaceuticals made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #707 holding.
  • Carmichael Hill & Associates first reported a position in Corbus Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Carmichael Hill & Associates's Corbus Pharmaceuticals position peaked at $8K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.